Maharashtra FDA Notices Bollywood Stars Over Vimal Elaichi Ad: Why Tukaram Mundhe’s Action Is Drawing Attention

A fresh controversy has emerged around a Vimal Elaichi advertising campaign after the Maharashtra Food and Drug Administration (FDA) issued show-cause notices to Bollywood actors Shah Rukh Khan, Ajay Devgn and Tiger Shroff. The regulator has questioned whether the advertisement indirectly promotes a prohibited pan masala product through what is commonly described as surrogate advertising.

The action has brought renewed attention to the relationship between celebrity endorsements, brand advertising and public-health regulations. It has also placed Maharashtra FDA Commissioner Tukaram Mundhe at the centre of the debate over how aggressively authorities should act against promotions that may cross regulatory boundaries.

Why the Vimal Elaichi Advertisement Is Under Scrutiny

The three actors appeared together in a Vimal Elaichi campaign. While the advertised product is presented as elaichi, the Maharashtra FDA has raised concerns about the broader brand identity associated with Vimal and whether the campaign amounts to indirect promotion of pan masala.

The regulator's position is that advertisements cannot be assessed only by looking at the product named in the commercial. The overall presentation, brand association and the possible impact on consumers can also become relevant when determining whether an advertisement is misleading or indirectly promotes a restricted product.

Maharashtra has maintained restrictions on tobacco and nicotine-containing products, and the FDA's recent action comes amid a wider enforcement campaign focused on food safety, advertising practices and products that could pose risks to consumers.

Actors Asked to Respond Within 15 Days

The notices reportedly give Shah Rukh Khan, Ajay Devgn and Tiger Shroff 15 days to respond. The FDA has sought information connected with their participation in the campaign and has asked for relevant documentation surrounding the advertisement.

The regulator has also directed that promotional material connected with the campaign should be discontinued or removed from relevant digital platforms while the matter is examined. The notices seek information that could help establish how the advertisement was created, promoted and commercially arranged.

This means the immediate issue is not a final finding of wrongdoing against the actors. The notices are part of the regulatory process through which the FDA is seeking explanations and supporting documents before deciding what further action, if any, may be appropriate.

The Law Behind the FDA's Action

The Maharashtra FDA has referred to provisions of the Food Safety and Standards Act, 2006, particularly rules dealing with misleading food advertisements. Section 24 places restrictions on advertisements that are false, misleading or deceptive, while Section 53 provides for penalties in cases involving misleading advertisements.

Mundhe has also stressed that responsibility can extend beyond the manufacturer. According to his recent comments, people involved in creating, publishing, sponsoring or endorsing an advertisement may have responsibilities under the applicable regulations.

That approach could have implications beyond this particular Vimal campaign. Celebrity endorsements are a major part of India's advertising industry, and regulators are increasingly examining whether well-known personalities have taken adequate steps to understand the products and claims they promote.

Who Is Tukaram Mundhe?

The controversy has also revived public interest in Tukaram Mundhe, an IAS officer known for his strict administrative style and willingness to take action against businesses and institutions.

Mundhe's current campaign extends beyond celebrity advertising. Under his leadership, the Maharashtra FDA has intensified inspections of restaurants, food businesses and quick-commerce facilities. Reuters recently reported that the agency inspected dozens of establishments and suspended permits at several warehouses after finding serious hygiene-related problems.

His approach has attracted both support and criticism. Supporters view the aggressive enforcement as an effort to make food-safety regulations meaningful, while critics have questioned whether regulatory powers are sometimes exercised too forcefully. The Bombay High Court recently raised concerns over the proportionality of an FDA action involving a pharmaceutical company, highlighting the importance of following due process while enforcing regulations.

A Larger Debate Over Celebrity Advertising

The Vimal controversy therefore goes beyond three Bollywood stars or one advertisement. It raises a broader question: how much responsibility should celebrities carry when endorsing products connected to major consumer brands?

For audiences, celebrities can give products an immediate sense of credibility and popularity. That influence is precisely why regulators are increasingly examining whether endorsements comply with advertising and consumer-protection rules.

Mundhe's message has been clear: regulatory requirements apply across the advertising chain, regardless of how famous or powerful an individual may be.

The three actors now have an opportunity to respond to the notices and provide the documents requested by the FDA. Their explanations, along with the regulator's assessment, will determine what happens next.

For now, the case has placed surrogate advertising and celebrity accountability firmly back in the spotlight—and Maharashtra's latest action suggests that regulators are prepared to examine high-profile campaigns as closely as ordinary commercial promotions.